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T cell activationThe caspase inhibitors, benzyloxycarbony (Cbz)-l-Val-Ala-Asp (OMe)-ﬂuoromethylketone (z-VAD-FMK) and
benzyloxycarbonyl (Cbz)-Ile-Glu (OMe)-Thr-Asp (OMe)-FMK (z-IETD-FMK) at non-toxic doses were found
to be immunosuppressive and inhibit human T cell proliferation induced by mitogens and IL-2 in vitro.
Both caspase inhibitors were shown to block NF-κB in activated primary T cells, but have little inhibitory ef-
fect on the secretion of IL-2 and IFN-γ during T cell activation. However, the expression of IL-2 receptor
α-chain (CD25) in activated T cells was inhibited by both z-VAD-FMK and z-IETD-FMK, whereas the expres-
sion of the early activated T cell marker, CD69 was unaffected. During primary T cell activation via the antigen
receptor, both caspase-8 and caspase-3 were activated and processed to their respective subunits, but neither
caspase inhibitors had any effect on the processing of these two caspases. In sharp contrast both caspase in-
hibitors readily blocked apoptosis and the activation of caspases during FasL-induced apoptosis in activated
primary T cells and Jurkat T cells. Collectively, the results demonstrate that both z-VAD-FMK and z-IETD-FMK
are immunosuppressive in vitro and inhibit T cell proliferation without blocking the processing of caspase-8
and caspase-3.
© 2012 Elsevier Inc. Open access under CC BY license.Introduction
The important role of caspases, particularly caspase-8 in T cell ac-
tivation and proliferation is now ﬁrmly established (Chun et al.,
2002). However, much of the early evidence for the role of caspase in-
volvement in mitogen-induced T cell proliferation came largely from
studies using peptidyl-FMK caspase inhibitors, which were shown to
markedly decrease mitogen-induced T cell proliferation (Alam et al.,
1999; Boissonnas et al., 2002; Falk et al., 2004; Kennedy et al., 1999;
Mack and Hacker, 2002). Besides blocking mitogen-induced T cell
proliferation (Chun et al., 2002; Falk et al., 2004) these caspase inhib-
itors were also shown to reduce the expression of the α-subunit of
the IL-2 receptor, CD25 and inhibit IL-2 secretion in activated T cells
(Falk et al., 2004; Kennedy et al., 1999).
All peptidyl-FMK caspase inhibitors contain a peptide sequence
based on the target cleavage sequence of the substrate and act as com-
petitive inhibitors bymimicking the substrate. These enzymes recognise
a sequence of four amino acids in the substrates, designated P4-P3-P2-P1
and cleave substrates after an Asp residue at P1 (Yuan et al., 1993). All
peptide-based caspase inhibitors used to date consist of a peptide
sequence culminating in an Asp residue (Garcia-Calvo et al., 1998). Thehow).
 license.requirement for speciﬁc amino acid residues at the other positions varies
with members of the caspase family. This enables more speciﬁc caspase
inhibitors to be developed by exploiting the different substrate speciﬁc-
ities (Garcia-Calvo et al., 1998; Thornberry et al., 1997). Conjugated to
the peptide sequence of the caspase inhibitor is a halomethylketone,
such as ﬂuoromethylketone (FMK), which form irreversible covalent
bonds with the S-H group of the cysteine residue in the caspase active
site (Caserta et al., 2003; Garcia-Calvo et al., 1998). Finally, the
amino-terminal group, usually a benzyloxycarbonyl (z) or acetyl (Ac)
group, enhances the cell permeability of the inhibitor by increasing the
hydrophobicity of the compound (Van Noorden, 2001).
These peptidyl-FMK caspase inhibitors are extremely useful tools
and were used extensively in apoptosis research to elucidate the
role of caspases during apoptotic cell death. However, accumulating
evidence also suggests that these inhibitors may not be as speciﬁc
as originally anticipated. For instance, the widely-used broad-
spectrum caspase inhibitor, z-VAD-FMK, has also been shown to
inhibit other enzymes, such as the lysosomal cysteine protease, ca-
thepsin B (CatB) (Schotte et al., 1999), peptide:N-glycanase (PNGase)
(Misaghi et al., 2006) and picornaviral 2A proteinases (Deszcz et al.,
2004). In addition, the caspase-8 inhibitor, z-IETD-FMK also inhibited
picornaviral 2A proteinases (Deszcz et al., 2004). Some of the
non-speciﬁc effects of these caspase inhibitors (z-VAD-FMK and
z-IETD-FMK) may account for their inconsistencies in blocking T cell
activation and proliferation as reported in a number of early studies
(Mack and Hacker, 2002; Zapata et al., 1998). In addition, the
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liferation (Alam et al., 1999), was subsequently shown to have little
effect in other studies (Boissonnas et al., 2002; Kennedy et al., 1999;
Mack and Hacker, 2002).
In the present study we examined the immunosuppressive prop-
erties of the peptidyl-FMK caspase inhibitors, z-VAD-FMK and
z-IETD-FMK, and determined whether their inhibition of mitogen-
induced T cell proliferation is due to the blocking of caspase process-
ing during T cell activation. Our results showed that both caspase
inhibitors readily block T cell proliferation induced by mitogens as
well as IL-2. However, these peptidyl-FMK caspase inhibitors had
little effect on the processing of caspase-8 and caspase-3 to their
respective subunits during T cell activation although they efﬁciently
blocked caspase activation during apoptosis. Taken together, these
results suggest that the inhibition of T cell proliferation mediated by
these caspase inhibitors is independent of their caspase inhibition
properties.
Materials and Methods
Reagents. Benzyloxycarbonyl-Val-Ala-Asp-(O-methyl)-ﬂuoromehyl-
ketone (z-VAD-FMK), benzyloxycarbonyl-Ile-Glu-Thr-Asp-ﬂuorometh-
ylketone (IETD-FMK) and benzyloxycarbonyl-Phenyl-Alanyl-acid-
ﬂuoromethylketone (z-FA-FMK) were purchased from ICN (USA).
Monoclonal antibody (mAb) against CD3 (clone OKT3) was puriﬁed
from hybridoma (ATCC) culture supernatants and anti-CD28 mAb was
purchased from R & D (UK). Goat-anti caspase-8 was from Santa Cruz
Biotechnology (USA) and rabbit anti-caspase-3 was generous gift from
Xiao-Ming Sun, MRC Toxicology Unit (UK). FITC-conjugated anti-CD25
and RPE-conjugated anti-CD69were acquired fromTransduction Labora-
tories (UK) and Dako (UK), respectively. Recombinant Fas ligand (FasL),
anti-Flag and anti-PARP were obtained from Alexis Biochemicals (UK).
[3H]-thymidine was obtained from Amersham (UK) and phytohaema-
glutinin (PHA) was purchased from Sigma (UK). MACS columns and
MACS beads conjugated with anti-CD4 and anti-CD8 were obtained
from Miltenyi Biotec (Germany). Lymphoprep was from Axis-Shield
PoCAS (Norway) and RPMI 1640 and FCSwere fromGibco (UK). Hoechst
33358 and carboxyﬂuorescein diacetate succinimidyl ester (CFSE) were
fromMolecular Probes (USA).
Cell isolation. Peripheral venous blood was obtained from normal
healthy volunteers and collected into heparinized Vacutainers (Becton
Dickinson). Peripheral blood mononuclear cells (PBMCs) were isolated
using density gradient centrifugation with lymphoprep. The cells at the
interface between the plasma and lymphoprep were collected, washed
and re-suspended in RPMI containing 10% (v/v) foetal calf serum
(FCS), 10 mM L-glutamine (Invitrogen, UK), penicillin (100 U/ml)
and streptomycin (100 μg/ml). The viability of the lymphocyte popula-
tion obtained via this procedure was routinely >95% as assessed
by trypan blue exclusion assay. Puriﬁed CD4+ (~97%) and CD8+ T
(~98%) cells were isolated from the PBMCs using anti-CD4 and
anti-CD8 mAbs conjugated MACS beads.
Cell cultures and treatments. PBMCs (5×106 cells/ml) or puriﬁed
CD4+ and CD8+ T cells (1×106 cells/ml) in RPMI 1640 supplemented
with 10% FCS were stimulated with either 5 μg/ml PHA, co-stimulated
with plate bound 5 μg/ml anti-CD3 (OKT3 mAb) and 2.5 μg/ml
anti-CD28 in the absence or presence of caspase inhibitors for various
time periods in an atmosphere of 5% CO2 in air at 37 °C. Proliferating T
cells were derived by activating puriﬁed CD4+ and CD8+ T cells with
PHA for 24 h and then reseeded in media supplemented with rIL-2
(25 Units/ml). The activated T cells were cultured for 7 days prior to
use. The human leukemic T cell line, Jurkat, clone E6-1 (ATCC) were
maintained in logarithmic phase of growth in RPMI 1640 supplemented
with 10% FCS and 2 mM L-Glutamine in an atmosphere of 5% CO2
in air at 37 °C. To induce apoptosis, Jurkat T cells (1×106 cells/ml) oractivated T cells (1×106 cells/ml) in completemediumwere stimulated
with recombinant Flag-tagged FasL (100 ng/ml) followed by cross-
linking with anti-Flag (1 μg/ml) for 16 h. Apoptotic cells were deter-
mined using UV microscopy, annexin V staining and TMRE labelling of
mitochondria as previously described (Jayaraman, 2005; Johnson et
al., 2000). Cell viability was determined by suspending treated cells in
500 μl ice-cold PBS with 10 μl of 20 μg/ml propidium iodide (PI) and
the uptake of PI was analysis using ﬂow cytometry.
Cell proliferation and division assays. T cell proliferation following
mitogen stimulation was determined using [3H]-thymidine incorpora-
tion. In brief, PBMCs or puriﬁed T cells were seeded at 1×106 cells/ml
in 96 well plates and stimulated with either PHA (5 μg/ml) or
co-stimulated with anti-CD3 mAb (5 μg/ml) and anti-CD28 mAb
(2.5 μg/ml) in the presence or absence of caspase inhibitors. The cells
were cultured for 72 h with the last 16 h pulsed with [3H]-labelled
methyl-thymidine (0.037 MBq) prior to harvest onto glass ﬁbre ﬁlter
mats using a Tomtec automated multi-well harvester (Perkin Elmer
Life Sciences, Boston USA). Wallac Betaplate scintillation reagent
(Perkin Elmer Life Sciences) was added to the glass ﬁbre ﬁlter mats
and the radioactivity was determined on a 1450 Microbeta liquid
scintillation counter (Perkin Elmer Life Sciences, Boston USA). T lym-
phocyte division following mitogen stimulation was determined using
CFSE labelling of the cells (Lyons and Parish, 1994). In brief, PBMCs
were suspended in PBS at a density of 5×107/ml and incubated with
5 μM CFSE at 37 °C for 10 minutes. Following incubation with CFSE
the labelled PBMCs were washed twice in RPMI to remove excess
CFSE. The CFSE labelled cells were treated with mitogens as previously
described in the presence or absence of caspase inhibitors. As the T
lymphocytes divide, CFSE is sequentially diluted, resulting in a de-
creased in ﬂuorescence intensity in the cells, which can be followed
by ﬂow cytometry.
Measurement of secreted IL-2 and IFN-γ in culture supernatants.
Following treatments for 24 h, the T cellswere removed by centrifugation
and the supernatants collected and kept frozen until used. The secreted
IL-2 and IFN- in the supernatants were detected using the DuoSet ELISA
kits from R & D System (UK) according to the manufacturer's instruction.
Determination of cell surface CD25 and CD69 expression. Following
treatments, PBMCs (5×105 cells) were centrifuged down and the
supernatants discarded. The cell pellets were re-suspended in 50 μl
staining buffer (2% BSA in PBS). FITC-conjugated anti-CD25 (10 μl),
RPE-conjugated anti-CD69 (10 μl) or the appropriate ﬂuorochrome-
conjugated mouse IgG (isotype control) were added to the cells
and incubated on ice for 30 min in the dark. The cells were then
washed twice in staining buffer before analyzed immediately by ﬂow
cytometry.
Nuclear translocation of NF-κB RelA, p65. This is essentially as de-
scribed previously (Su et al., 2005). Puriﬁed T cells (3×106 cells)
were co-stimulated with anti-CD3 and anti-CD28 for 2 h, washed
with cold PBS and ﬁxed with 1 ml paraformaldehyde (4%) for 20 min
at room temperature. The cells were permeabilised with PBS containing
3% BSA and 0.2% triton X-100 for 2 min in room temperature. The
permeabilised cells were washed twice and resuspended in 100 μl of
PBS with 3% BSA and rabbit anti-p65 antibody (1:50 dilution) for
45 min at room temperature. The cells were then washed and incubat-
ed with anti-rabbit antibody conjugated with alexa ﬂuor (1:2000 dilu-
tions) and Hoechst 33348 in a ﬁnal volume of 200 μl for 30 min in
the dark. Following this the cells were washed twice and resuspended
in 10 μl PBS: glycerol (50/50, vol/vol). The cells were mounted onto
slides and viewed using confocal microscopy. Images were randomly
acquired from each sample and cells with NF-κB p65 nuclear localiza-
tion were counted. A minimum of 500 cells was analyzed for each
sample.
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Fig. 1. Dose-dependent inhibition of T cell proliferation by peptidyl FMK caspase inhibitors. T cell proliferation in PBMCs co-stimulation with anti-CD3 and anti-CD28 (A) or
stimulated with PHA (B) alone in the presence or absence of various concentrations of z-VAD-FMK and z-IETD-FMK. T cell proliferation was assayed using [3H]-thymidine incor-
poration. The toxicity of both caspase inhibitors was assessed after 24 h in resting T cells and after 72 h in activated T cells using PI uptake (C). Activated T cells undergoing cell
division (72 h) are measured using CFSE labelling (D). The results are the means±SEM from three separate experiments (A, B and C), and one representative from three indepen-
dent separate experiments (D). DMSO was used as the carrier solvent.
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in PBS and resuspended in 30 μl lysis buffer (0.1 M NaCl, 1 mM Tris
HCl at pH7.6, 1 mM EDTA, 1% Triton-X, 1 mM PMSF). The cells in lysisbufferwere taken through 3x freeze/thaw cycles on dry ice. Protein con-
centration was measured using the Bradford assay (Biorad, Germany).
Protein (30 μg) from whole-cell lysates was diluted in loading buffer
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Fig. 2. The effect of z-VAD-FMK and z-IETD-FMK on cytokine secretion in activated T cells.
Puriﬁed CD4+ and CD8+ T cells were co-stimulatedwith anti-CD3 and anti-CD28 for 24 h
in the presence and absence of z-VAD-FMK or z-IETD-FMK. The amount of IL-2 (A) and
IFN-γ (B) secreted into the culture supernatants were determined using ELISA as
described inMaterials andMethods. Results are themeans±SEM from three independent
experiments. ND, not detected. DMSO was used as the carrier solvent.
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and 100 mM DTT) and resolved using SDS-polyacrylamide gel electro-
phoresis. The polyacrylamide gels used were 7% for PARP and 13% for
caspases. The separated proteins were transfer onto Hybond C mem-
brane (Amersham, UK) and probed with antibodies to caspase-8,
caspase-3 and PARP. Detection was carried out using chemilumines-
cence (Amersham).
Statistical analysis of the data. The experimental data were analysed
using Student's t test or One-way analysis of variance followed by
Dunnet's test.
Results
Effect of z-VAD-FMK and z-IETD-FMK on primary T cell proliferation
In order to determine the immunosuppressive effects of peptidyl-
FMK caspase inhibitors on T cell activation, the effects of z-VAD-FMK
and z-IETD-FMK on mitogen-induced T cell proliferation were exam-
ined. These two inhibitors were chosen because the former is a
pan-caspase inhibitor and the latter a preferred caspase-8 inhibitor.
As illustrated in Fig. 1A, z-VAD-FMK dose-dependently inhibited T
cell proliferation mediated through the co-stimulation with anti-
CD3 and anti-CD28. The caspase-8 inhibitor, z-IETD-FMK was less ef-
fective at 25 and 50 μM, but inhibited T cell proliferation to a similar
extent as z-VAD-FMK at the higher concentration (100 μM). A similar
dose-dependent inhibition was seen with these two peptidyl-FMK
caspase inhibitors on PHA-induced T cell proliferation (Fig. 1B).
Taken together, these data conﬁrmed previous published ﬁndings
that both z-VAD-FMK and z-IETD-FMK inhibit mitogen-induced T
cell proliferation (Alam et al., 1999; Boissonnas et al., 2002). We
next examined whether the decreased in [3H]-thymidine incorpora-
tion in the presence of these caspase inhibitors was due to direct tox-
icity of these inhibitors. To this end, the cell viability of primary T cells
following treatment with the peptidyl-FMK caspase inhibitors was
determined. As shown in Fig. 1C, there was no increased in PI uptake
in resting T cells after 24 h treatment with z-VAD-FMK or z-IETD-
FMK compared to control untreated cells. This suggests that the
caspase inhibitors are not toxic to resting T cells. To further rule out
toxicity following T cell activation, PI uptake was also examined in
activated T cells in the presence of caspase inhibitors. About 9% of
control activated T cells took up PI after activation, whereas in the
presence of 100 μM of z-VAD-FMK and z-IETD-FMK cell death
increased to 18% and 23%, respectively (Fig. 1C). The increase in PI up-
take was not signiﬁcant (p>0.05) suggesting that the marked inhibi-
tion of T cell proliferation is unlikely to be due to the toxicity of these
inhibitors. To further corroborate the [3H]-thymidine incorporation
results (Figs. 1A & B) we examined the effect of the caspase inhibitors
on T cell division using CFSE labelling (Lyons and Parish, 1994). The
sequential dilution of the CFSE dye following cell division can be followed
using ﬂowcytometry. As illustrated in Fig. 1D, the cellular ﬂuorescence
intensity remained high in resting T cells over 72 h, conﬁrming that the
cells were quiescent. In contrast, T cells co-activated with anti-CD3 plus
anti-CD28were dividing as indicated by the sequential decrease in cellu-
lar ﬂuorescence intensity. In the presence of z-VAD-FMK, the decrease in
cellular ﬂuorescence intensity was markedly inhibited compared with
control activated cells, suggesting that cell division was blocked. This
effect was more apparent at 100 μM, where nearly all the cells retained
a high cellular ﬂuorescence. In contrast, little effect on cell division was
seen with 50 μM z-IETD-FMK, but again at 100 μM, cell division was
markedly inhibited to similar extent as z-VAD-FMK. Compared with co-
stimulation with anti-CD3 plus anti-CD28, more resting T cells undergo
cell division following exposure to PHA (Fig. 1D) as illustrated by the
marked decrease in ﬂuorescence after 72 h of activation. We observed
that z-VAD-FMK at 50 μMhad little effect on PHA-induced T cell prolifer-
ation and inhibitionwas only seen at 100 μM.A similar inhibition patternwas seenwith z-IETD-FMK, although this inhibitor appeared to be slight-
ly less potent compared with z-VAD-FMK. These data are very much in
line with the [3H]-thymidine incorporation data indicating that both
caspase inhibitiors are capable of inhibiting T cell proliferation induced
by anti-CD3 plus anti-CD28 or PHA. DMSO (>0.1%), which is the carrier
solvent for the caspase inhibitors was included in all the studies andwas
found to have no effect on T cell proliferation (results not shown).
Effects of peptidyl-FMK caspase inhibitors on interleukin 2 (IL-2) secretions
and signalling
Following T cell activation, IL-2 is synthesised and secreted, which
subsequently stimulates T cells in an autocrine and paracrine fashion
to drive T cell proliferation (Nelson, 2004). To determine the underlying
mechanism of the caspase inhibitor-mediated inhibition of mitogen-
induced T cell proliferation, we examined whether IL-2 secretion was
affected. As shown in Fig. 2A, control untreated cells secrete little IL-2,
whereas following co-stimulation with anti-CD3 and anti-CD28 there
was a marked increase in IL-2 secretion into the culture supernatant
as detected using ELISA. Neither z-VAD-FMK nor z-IETD-FMK had any
signiﬁcant effect on IL-2 secretion following T cell activation. We next
determined whether these two caspase inhibitors had any effect on
IFN-γ secretion following T cell activation. As illustrated in Fig. 2B, sim-
ilar to IL-2 secretion, both z-VAD-FMK and z-IETD-FMK had no signiﬁ-
cant effect on the production of IFN-γ in activated T cells. We next
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Fig. 3. The effect of z-VAD-FMK and z-IETD-FMK on CD25 and CD69 expression in T cells following activation. The T cells in PBMCs were co-stimulated with anti-CD3 and anti-CD28
in the presence and absence of z-VAD-FMK and z-IETD-FMK for 48 h. The cells were then incubated with FITC-conjugated anti-CD25 or anti-CD69 before analysis using
ﬂowcytometry as described in Materials and Methods. The results are from one representative from of three independent experiments.
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tor (CD25) is affected by these caspase inhibitors. Since T cell prolif-
eration following activation is IL-2 driven, a decrease in CD25 will
ultimately decrease cell proliferation and division. As shown in Fig. 3,
the percentage of cells that stained positive for CD25 expression in-
creased from around 4% in the control untreated cells to approximately
60% following activation with anti-CD3 plus anti-CD28. In the presence
of z-VAD-FMK the up-regulation of CD25was reduced to 46% and 31% at
50 μMand 100 μM, respectively. z-IETD-FMKwas slightly less effective,
reducing the percentage of activated T cells expressing CD25 to 52% and
35% at 50 μM and 100 μM, respectively. However, both caspase inhibi-
tors had little effect on the expression of CD69, an early T cell marker
which is stored preformed in the cytoplasm prior to expression on the
cell surface (Risso et al., 1991). These ﬁndings suggest that both of
these peptidyl-FMK inhibitors may render the cells unresponsive to
IL-2 through the inhibition of CD25 expression. To examine this, the
effect of the peptidyl-FMK inhibitors on IL-2 driven T cell proliferation
was determined. Puriﬁed primary T cells were activated for 7 days,
washed and the proliferating T cells cultured in medium supplemented
with rIL-2 (25 U/ml) in the presence of the peptidyl-FMK inhibitors. In
this approach the cycling T cells already express high level of IL-2R on
the cell surface; hence the presence of rIL-2 should drive T cellproliferation. As illustrated in Fig. 4A the control cycling T cells in
the presence of rIL-2 continued to proliferate as shown by the uptake
of [3H]-thymidine. In the presence of z-VAD-FMK the uptake of [3H]-
thymidine was inhibited in a dose-dependent manner whereas
z-IETD-FMK was less effective. Our results suggest that antigen and
IL-2 driven T cell proliferation are sensitive to the caspase inhibitors.
We next examined whether these two peptidyl-FMK have any effect on
normal cell growth in a T cell line that do not require activation signal to
drive proliferation. To this end, the T cell leukemia cell line, Jurkat was
cultured in the presence of these caspase-inhibitors. As shown in
Fig. 4B, both peptides have no effect on Jurkat cell growth suggesting
that the caspase inhibitors maybe targeting activation signals lead-
ing to cell proliferation.
Peptidyl-FMK caspase inhibitors blocked the nuclear translocation of NF-κB
RelA (p65) in activated T lymphocytes
Because NF-κB is a well characterised transcription factor that is
required for IL-2, IFN-γ and CD25 gene transcription as well as IL-2
signalling and T cell activation (Mortellaro et al., 1999), we examined
the effect of the caspase inhibitors on the signalling of this transcrip-
tion factor. The nuclear translocation of p65 (RelA) following TCR
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Fig. 4. Effect of z-VAD-FMK and z-IETD-FMK on IL-2-driven T cell proliferation and nor-
mal Jurkat T cell growth. (A) Preactivated T cells were cultured in medium
supplemented with rIL-2 in the absence or presence of the caspase inhibitors for
72 h. The incorporation of [3H]-thymidine was determined as outlined in Materials
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as previously reported (Lawrence et al., 2006). Following activation
with anti-CD3 plus anti-CD28 for 2 h, the translocation of RelA into
the nucleus was detected in ~58% of the activated T cells (Fig. 5) indi-
cating that the NF-κB signalling was activated. In the presence of
z-VAD-FMK (50 μM and 100 μM), there was a signiﬁcant decrease
in nuclear translocation of p65 in activated T cells, whereas only
100 μM z-IETD-FMK signiﬁcantly inhibited p65 translocation. Taken
together, these data suggest that the peptidyl-FMK caspase inhibitors
inhibit NF-κB activation, which to some extent helps to explain the
inhibition of T cell activation and proliferation, CD25 expression and
IL-2 driven T cell proliferation.Time dependent processing of caspase-8 and caspase-3 during primary T
cell activation
Previous studies have implicated the blocking of T cell proliferation
by caspase inhibitors via the inhibition of caspases (Alam et al., 1999;
Boissonnas et al., 2002; Falk et al., 2004; Kennedy et al., 1999;
Mack and Hacker, 2002). To examine this we ﬁrst determined
the time course for caspase-8 and caspase-3 activation in T cells co-stimulated with anti-CD3 plus anti-CD28. As illustrated in Fig. 6A, no
caspase-8 or caspase-3 processing was observed in resting primary T
cells. However, following co-stimulation with anti-CD3 plus anti-
CD28, a time-dependent processing of caspase-8 and caspase-3 into
their respective intermediate subunits of p42/p43 and p20 was ob-
served after 12 h. By 48 h caspase-8 and caspase-3 were further
processed and the p20 subunit of caspase-3 was further cleaved to
the p19 fragment. Based on these results the 24 h time-point was
chosen for subsequent experiments. Since caspase processing is syn-
onymous with apoptosis, several assays were used to rule out apopto-
sis in these activated T cells. As depicted in Fig. 6B, neither the control
nor the activated T cells stained positive with FITC-conjugated
annexin V, suggesting that the activated T cells were not apoptotic.
The nuclei of these activated T cells remained normal without any
apoptotic nuclei characteristics (nuclear condensation) following
Hoechst dye staining (results not shown) and the cells had an intact
mitochondrial membrane potential (Fig. 6C) as determined by TMRE
staining of the mitochondrial membrane potential (Jayaraman, 2005;
Johnson et al., 2000). Finally, the caspase-3 substrate, PARP which is
cleaved during apoptosis, (Kaufmann et al., 1993) remained intact in
these activated T cells (Fig. 6D). Taken together, these data demon-
strated that the activation of caspase-8 and caspase-3 in activated T
cells following activation was not due to the induction of apoptosis.z-VAD-FMK and z-IETD-FMK have no effect on the processing of caspase-
8 and caspase-3 during primary T cell activation
Although previous studies have shown that both caspase inhibitors
readily blocked T cell proliferation, it is not clear whether the activation
of caspases during T cell activation is inhibited (Alam et al., 1999;
Boissonnas et al., 2002). To examine this, puriﬁed resting T cells were
pre-treated for 30 min with various concentrations of z-VAD-FMK or
z-IETD-FMK prior to co-stimulation with anti-CD3 plus anti-CD28. As
shown in Fig. 7, the western blot analysis showed that neither
z-VAD-FMK nor z-IETD-FMK up to 100 μMhad any effect on the activa-
tion of caspase-8 following T cell activation as shown by the presence of
p42/43 cleaved intermediates. Similarly, both caspase inhibitors have
little effect on the processing of caspase-3 to the p20 subunit, although
they partially inhibited the processing of the p20 subunit to the smaller
fragments. These results demonstrated that both caspase inhibitors
have no effect on the activation of caspase-8 and caspase-3 in T cells
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109C.P. Lawrence, S.C. Chow / Toxicology and Applied Pharmacology 265 (2012) 103–112following co-stimulation with anti-CD3 and anti-CD28. To conﬁrm that
z-VAD-FMK and z-IETD-FMK block caspase activity, we examined their
effects on caspase processing in activated primary T cells (Fig. 8) and
Jurkat T cells (Fig. 9) undergoing FasL-mediated apoptosis. As shown
in Fig. 8A, activated T cells undergo apoptosis readily when treatedwith FasL for 16 h which was effectively blocked by z-VAD-FMK
(50 and 100 μM). As expected, western blot analysis showed that
some caspase-8 and caspase-3 were processed in control activated
T cells (Fig. 8B), and more were processed to their respective subunits,
p42/43 and p19/17 during FasL-induced apoptosis. The presence of
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Fig. 7. Effect of peptidyl FMK inhibitors on caspase processing in activated T cells. Puriﬁed T cells were co-activated with anti-CD3 and anti-CD28 for 24 h in the presence of
z-VAD-FMK or z-IETD-FMK. Whole cell lysates (20 μg protein) were resolved on 13% SDS-PAGE and transferred to nitrocellulose membrane prior to probing for caspase-8 and
caspase-3 as outlined in Materials and Methods. Results are one representative from three independent experiments. DMSO was used as the carrier solvent.
110 C.P. Lawrence, S.C. Chow / Toxicology and Applied Pharmacology 265 (2012) 103–112z-VAD-FMKpartially inhibited the processing of caspase-8 and caspase-3,
suggesting that it may be blocking the caspases that were activated dur-
ing apoptosis and not those processed during cell activation. In contrast,
z-FA-FMK which is a control for z-VAD-FMK hardly has any effect on
FasL-induced cell death and the activation of caspase-8 and caspase-3 in
activated T cells. Similarly, both z-VAD-FMK and z-IETD-FMK inhibited
FasL-induced apoptosis and blocked the activation of caspase-8 and
caspase-3 in Jurkat T cells, whereas z-FA-FMK has little effect (Figs. 9A
& B). Taken together, these data suggest that z-VAD-FMK and z-IETD-
FMK inhibit caspase processing during apoptosis but not during T cell
activation. In contrast, z-FA-FMK has no effect on caspase processing
during apoptosis and did not block FasL-induced apoptosis in activated
T cells and Jurkat T cells.
Discussion
The role of caspases, in particular caspase-8, during T cell activation
and proliferation is now well established, although their function in
regulating proliferation is still unclear. Some of the earliest evidence
to support caspase involvement in T cell proliferation came from studies
using peptidyl-FMK caspase inhibitors. These compounds were shown
to markedly reduce mitogen-induced T cell proliferation, suggesting
that caspase enzymatic activity is required for T cell activation and pro-
liferation (Alam et al., 1999; Boissonnas et al., 2002; Kennedy et al.,
1999; Mack and Hacker, 2002) (Falk et al., 2004). However, accumu-
lating evidence suggests that the peptidyl-FMK caspase inhibitors,
which have been widely used in apoptosis research, may be associated
with non-speciﬁc effects (Deszcz et al., 2004; Misaghi et al., 2006;
Schotte et al., 1999). In the present study, we examinedwhether the in-
hibition of mitogen-induced T cell proliferation by the broad-spectrum
caspase inhibitor, z-VAD-FMK and the caspase-8 selective inhibitor,
z-IETD-FMK is mediated through the inhibition of caspases.
In agreement with several reports (Alam et al., 1999; Boissonnas
et al., 2002; Falk et al., 2004; Kennedy et al., 1999; Mack and
Hacker, 2002), we showed that mitogen-induced T cell proliferation
was readily inhibited by z-VAD-FMK and z-IETD-FMK. Besides anti-
gen induced T cell proliferation, IL-2 driven T cell proliferation was
also inhibited by these two caspase inhibitors although z-IETD-FMKwas less effective compared with z-VAD-FMK. In addition to blocking
T cell proliferation, these compounds were found to reduce the
expression of CD25, an early T cell activation marker which requires
gene transcription. Together with CD25, a wide variety of genes that
control immune responses are regulated by the NF-κB family of tran-
scription factors. The NF-κB complexes are localised in the cytoplasm
in resting T cells, where they are bound to inhibitor proteins (IκBs). In
T cells the predominant form of NF-κB complexes that are activated
during T cell activation is a heterodimer of the p65 subunit associated
with either p50 or p52 subunits, although xRel/p50 is also present
(Grilli et al., 1993; Tak and Firestein, 2001). Once activated, the inhibi-
tory proteins, IκB are rapidly phosphorylated and degraded, which in
turn releases the NF-κB transcription factors to be translocated into
the nuclei and together with AP-1, regulate transcription (Grilli et al.,
1993). In agreement with a previous study (Su et al., 2005) as well as
our own (Lawrence et al., 2006), a large number of primary T cells acti-
vated through the antigen receptor were stained positive for p65 in the
nucleus. In the presence of the caspase inhibitors, the nuclear transloca-
tion of p65 in activated primary T cells was signiﬁcantly reduced,
suggesting that NF-κB signalling induced by antigen receptor stimula-
tion is suppressed. This could account for the reduced expression of
CD25 since NF-κB regulated gene transcription is known to be required
for this process. In addition, the activation of NF-κB is also required for
IL-2 signalling (Mortellaro et al., 1999), which could explain the inhi-
bition of rIL-2 driven T cell proliferation in the presence of z-VAD-
FMK and z-IETD-FMK. However, neither z-VAD-FMK nor z-IETD-FMK
inhibited IL-2 or IFN-γ secretion, which is unexpected since NF- B sig-
nalling is also required for the transcription of these two cytokines
(Aronica et al., 1999; Hentsch et al., 1992). One explanation for this
could be insufﬁcient inhibition of NF-κB signalling by these compounds.
However, in addition to NF-κB signalling, antigen stimulated gene tran-
scription is also regulated by other transcription factors such as NFAT
and AP-1 (Hentsch et al., 1992; Luo et al., 1996). Therefore, it would
be interesting to determine the effects of these peptidyl-FMK inhibitors
on the activation of NFAT and AP-1 to reconcile these observations.
Besides promoting cell death, caspases have been shown to play
an important role in T cell activation (Chun et al., 2002). We showed
that following T cell activation through the antigen receptor, both
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111C.P. Lawrence, S.C. Chow / Toxicology and Applied Pharmacology 265 (2012) 103–112caspase-8 and caspase-3 were activated in the cells and this was inde-
pendent of any apoptotic characteristics. Surprisingly, both z-VAD-
FMK and z-IETD-FMK had virtually no effect on the processing of
caspase-8 and caspase-3 in these cells, which supports a previous
study where Boc-D-FMK, a broad-spectrum caspase inhibitor, has no
effect on caspase-3 processing during T cell activation (Bidere et al.,
2002). Our ﬁndings suggest that the processing of caspase-8 and
caspase-3 during T cell activation is mediated through a pathway
which is insensitive to z-VAD-FMK or z-IETD-FMK and is unlikely to
involve caspases. This is in contrast to FasL-induced apoptosis in
Jurkat T cells where the processing of both caspase-8 and caspase-3
was effectively blocked by z-VAD-FMK and z-IETD-FMK. More
importantly, we can infer from our results that the inhibition of anti-
gen driven T cell activation and proliferation by z-VAD-FMK and
z-IETD-FMK has little to do with the inhibition of caspase-8 and
caspase-3 processing. Taken together, these results suggest that the
processing of caspase-8 and caspase-3 during T cell activation is reg-
ulated by a distinct mechanism that is different from FasL-mediated
apoptosis.
The ﬁnding that caspase-8 and caspase-3 was processed in activated
T cells in the absence of apoptotic features, suggests that the apoptoticpathway must be inhibited at some stage downstream of caspase-8
and caspase-3 processing. In the present study, the caspase-3 substrate,
PARP remained intact, suggesting that caspase-3 activity was held in
check prior to the processing of PARP. This is in agreementwith previous
studywhere PARPwas not cleaved in activated T cells (Deas et al., 1998).
The ﬁnding that caspase-3 was only processed as far as the p20 subunit
in activated T cells does not account for the lack of PARP cleavage, since
removal of the N-terminal prodomain and thus generation of the p17
subunit from the p20 is not required for caspase-3 to cleave PARP
(Stennicke et al., 1998). However, in contrast to the ﬁndings in this
study, other studies have demonstrated PARP processing, in the absence
of apoptotic features in activated T cells (Alamet al., 1999;Wilhelm et al.,
1998). Therefore, themechanism for the prevention of apoptosis, despite
the presence of processed caspases remains to be determined.
In summary, the results presented here show that caspase pro-
cessing in activated T cells is not inhibited by z-VAD-FMK or z-IETD-
FMK. Since both z-VAD-FMK and z-IETD-FMK effectively inhibited T
cell proliferation, but had minimal effects on caspase processing in
activated T cells, it is unlikely that the inhibition of caspase processing
is the means by which they exert their inhibitory effect. Indeed, it has
recently been reported that z-VAD-FMK inhibits the enzymatically
active proform of caspase-8 which is required for TCR-mediated
NF-κB activation, rather than processed caspase-8 (Su et al., 2005).
Further work is required to determine whether z-VAD-FMK inhibits
pro-caspase-8 activity and whether z-IETD-FMK has a similar effect.
The ﬁnding that z-FA-FMK inhibited caspase-8 and caspase-3 pro-
cessing in activated T cells but did not inhibit caspases per se suggests
112 C.P. Lawrence, S.C. Chow / Toxicology and Applied Pharmacology 265 (2012) 103–112that it inhibits an upstream mediator of caspase processing during
T cell activation (Lawrence et al., 2006). Furthermore, the disparate
effects of these peptidyl-FMK inhibitors on caspase-8 and caspase-3
processing during T cell activation and Fas-mediated apoptosis sug-
gests that these processes are regulated by distinct mechanisms.
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